Edition:
India

PAION AG (PA8G.DE)

PA8G.DE on Xetra

2.37EUR
19 Feb 2018
Change (% chg)

€0.00 (+0.00%)
Prev Close
€2.37
Open
€2.35
Day's High
€2.39
Day's Low
€2.34
Volume
26,417
Avg. Vol
122,272
52-wk High
€3.53
52-wk Low
€2.15

Chart for

About

PAION AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In... (more)

Overall

Beta: 0.77
Market Cap(Mil.): €162.82
Shares Outstanding(Mil.): 61.12
Dividend: --
Yield (%): --

Financials

BRIEF-PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan

* SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN

18 Dec 2017

BRIEF-PAION announces clinical development progress with remimazolam

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER HANA PHARM IN SOUTH KOREA

23 Nov 2017

BRIEF-PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient

* ‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT

14 Nov 2017

BRIEF-PAION ‍9-mth net loss at 8.5 mln euros

* DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017

08 Nov 2017

BRIEF-Paion: Japan patent office grants dosing patent for remimazolam

* DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN

13 Oct 2017

BRIEF-PAION granted formulation patent for remimazolam in the EU

* DGAP-NEWS: PAION AG: EUROPEAN PATENT OFFICE GRANTS FORMULATION PATENT FOR REMIMAZOLAM IN THE EU

28 Sep 2017

Earnings vs. Estimates